Contract Pharma Manufacturing News

  1. SK pharmteco Collaborates With Axle Informatics And The National Institutes Of Health To Advance Rare Disease Gene Therapy Programs 5/7/2026

    SK pharmteco today announced a strategic partnership with Axle Informatics and the National Institutes of Health (NIH) to advance the development of gene therapies for rare diseases.

  2. Bristol Myers Squibb Licenses Antibody-Drug Conjugate Technology From Lonza 5/7/2026

    Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Bristol Myers Squibb, a global pharmaceutical company dedicated to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases, today announced an exclusive single-target licensing agreement.

  3. Halozyme And Oruka Announce Global Collaboration And License Agreement To Develop ORKA-001 With Hypercon Technology 5/6/2026

    Halozyme Therapeutics, Inc. (“Halozyme”) and Oruka Therapeutics, Inc. (“Oruka”) today announced that Halozyme’s wholly owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.

  4. Neuland Secures Development Collaboration With LIR Life Sciences For Transdermal GLP-1 5/6/2026

    Neuland Laboratories Limited, a global contract development and manufacturing organisation (CDMO) specialising in complex APIs, has entered into a development partnership with LIR Life Sciences Corp, a Canada-based biotechnology company focused on scalable and accessible obesity treatments, in advancing its cell-penetrating peptide (CPP) platform.

  5. Tissue Dynamics And Galmed Pharmaceuticals To Develop Human-Centered Chronic Cardiac Fibrosis Platform To Advance Aramchol-Based Therapeutics 5/6/2026

    Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a collaboration to develop a novel human chronic cardiac fibrosis model designed to accelerate the discovery and development of new Aramchol-based therapeutic approaches for complex fibrotic heart diseases.

  6. BioOra Limited And Wellington Zhaotai Therapies Limited (WZTL) Sign Heads Of Terms To Advance Their Global Expansion Of CAR T-Cell Therapy 5/6/2026

    BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, today announced the signing of a binding Heads of Terms agreement with Wellington Zhaotai Therapies Limited (Wellington Zhaotai) under which BioOra secures global rights to develop and commercialise Wellington Zhaotai's novel third-generation anti-CD19 CAR T-cell therapy for the treatment of multiple conditions (WZTL-002), including haematological malignancies and auto-immune diseases.

  7. Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support Of SiranBio's Dual-Target siRNA Program 5/5/2026

    Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end development and manufacturing solutions for structurally complex oligonucleotide therapeutics.

  8. Cellular Origins Advances Automation For Scalable Cell Therapy Manufacturing In Collaboration With Immatics 5/5/2026

    Cellular Origins, enabling the manufacturing of cell therapies at scale, today announced a collaboration with Immatics a late-stage clinical biopharmaceutical company and the global leader in precision targeting of PRAME for the production of Immatics’ immuno-oncology cell therapies.

  9. Viralgen Partners With Elaaj Bio To Advance Gene Therapy Program For CDKL5 Deficiency Disorder 5/5/2026

    Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 Deficiency Disorder (CDD).

  10. RoosterBio And Made Scientific Announce Strategic Technology And Supply Partnership To Expand Scalable MSC And Extracellular Vesicle Manufacturing 5/5/2026

    Made Scientific, Inc., a U.S.-based clinical and commercial cell therapy contract development and manufacturing organization (CDMO), and RoosterBio, Inc., a leading supplier of human mesenchymal stem cells (MSCs), engineered bioprocess media, and bioprocess development services, today announced a strategic partnership integrating RoosterBio's mesenchymal stem cell (MSC) and extracellular vesicle (EV) manufacturing platforms into Made Scientific's end-to-end CDMO offering which spans from initial process development through commercial-scale GMP manufacturing.